Last updated: July 11, 2026
PROFERDEX (Drug) Investment Scenario and Fundamentals Analysis: Patent Estate, Exclusivity Timeline, FDA Status, and Generic/Biosimilar Risk
PROFERDEX’s investability hinges on two controllables: (1) whether the product has enforceable exclusivity or usable patent coverage around the specific marketed strength/dosage form and (2) how close the FDA and patent pipeline dynamics place follow-on competitors (ANDAs under 505(b)(2) or 505(j) and, if biologic, biosimilars). A full fundamentals view requires PROFERDEX’s active ingredient, dosage form, FDA approval pathway, Orange Book listings, and any Paragraph IV challenges or ongoing litigations. Without those drug-specific identifiers, a complete and accurate patent/exclusivity and commercial risk profile cannot be produced.
What is PROFERDEX and what active ingredient does it contain?
Answer: Not determinable from the provided input.
Which dosage form and strength are marketed as PROFERDEX?
Answer: Not determinable from the provided input.
Is PROFERDEX FDA-approved or sold under an unapproved/compounding channel?
Answer: Not determinable from the provided input.
What patents protect PROFERDEX in the U.S., and how strong is the patent estate?
Answer: Not determinable from the provided input.
Which patent types matter for PROFERDEX (composition, formulation, method-of-use, or manufacturing)?
Answer: Not determinable from the provided input.
How many Orange Book listings cover PROFERDEX, and what are their key expiration dates?
Answer: Not determinable from the provided input.
Who are the patent assignees and NDA/holder(s) for PROFERDEX?
Answer: Not determinable from the provided input.
When does PROFERDEX lose exclusivity in the U.S.?
Answer: Not determinable from the provided input.
What are the likely exclusivity periods (NCE, pediatric, 7.5-year, 3-year, 6-year) that apply to PROFERDEX?
Answer: Not determinable from the provided input.
Do patents or exclusivity drive the actual end of launch protection for PROFERDEX?
Answer: Not determinable from the provided input.
What is the Orange Book status of PROFERDEX (listed drugs, patents, and exclusivity codes)?
Answer: Not determinable from the provided input.
What Orange Book codes (patent vs exclusivity) appear for PROFERDEX?
Answer: Not determinable from the provided input.
Which PROFERDEX patent entries are likely “bottle-neck” barriers for generics?
Answer: Not determinable from the provided input.
What patent litigation affects PROFERDEX, including Paragraph IV challenges and settlements?
Answer: Not determinable from the provided input.
Are there active or completed Paragraph IV ANDA litigations for PROFERDEX?
Answer: Not determinable from the provided input.
What are the settlement dates and “carve-out” terms for PROFERDEX (if any)?
Answer: Not determinable from the provided input.
Which generic companies are challenging PROFERDEX and what is their launch risk window?
Answer: Not determinable from the provided input.
What generic entry risks exist for PROFERDEX, and what launch date scenarios are most probable?
Answer: Not determinable from the provided input.
Does PROFERDEX face 505(j) generic approval or 505(b)(2) follow-on routes?
Answer: Not determinable from the provided input.
What formulation-change or method-of-use design-around routes could allow early entry?
Answer: Not determinable from the provided input.
How do patent expiration and 180-day exclusivity interact for PROFERDEX’s launch barrier?
Answer: Not determinable from the provided input.
Is PROFERDEX a biologic with biosimilar risk, or a small molecule facing ANDA risk?
Answer: Not determinable from the provided input.
If biologic, what biosimilar exclusivity and patent landscape controls PROFERDEX market share?
Answer: Not determinable from the provided input.
If small molecule, what ANDA pathways drive PROFERDEX generic timelines?
Answer: Not determinable from the provided input.
What formulations are protected for PROFERDEX (solid oral, injectable, topical, extended-release)?
Answer: Not determinable from the provided input.
Are there polymorph, salt form, particle size, crystallinity, or coating patents tied to PROFERDEX?
Answer: Not determinable from the provided input.
Are there manufacturing process patents (scale-up, purification, sterile fill-finish) relevant to PROFERDEX?
Answer: Not determinable from the provided input.
How does PROFERDEX compare with competitors in its therapeutic class on IP barriers and market exposure?
Answer: Not determinable from the provided input.
Which drugs are closest substitutes to PROFERDEX in prescribing patterns (same indication and similar dosing)?
Answer: Not determinable from the provided input.
How does PROFERDEX’s patent duration compare with class peers (weighted by likely generic entry timing)?
Answer: Not determinable from the provided input.
What is the FDA regulatory status of PROFERDEX (approval history, supplements, and labeling)?
Answer: Not determinable from the provided input.
What is the approval pathway (NDA 505(b)(1), 505(b)(2), 601 biologics license, or other)?
Answer: Not determinable from the provided input.
What labeling changes may create new patentable subject matter via supplements?
Answer: Not determinable from the provided input.
What are the commercialization fundamentals for PROFERDEX (revenue, market share, payer dynamics, and channel risk)?
Answer: Not determinable from the provided input.
What are PROFERDEX net sales and their trend (annual and quarterly), and what portion is exposed to substitution?
Answer: Not determinable from the provided input.
How do rebates, formulary placement, and channel inventory affect PROFERDEX earnings stability?
Answer: Not determinable from the provided input.
What is the growth dependency (new prescribers, adherence, or indication expansion)?
Answer: Not determinable from the provided input.
What investment thesis best fits PROFERDEX: growth, defense, or event-driven rerating?
Answer: Not determinable from the provided input.
Defensive thesis checklist (IP durability, litigation posture, and constrained generic design-around)
Answer: Not determinable from the provided input.
Growth thesis checklist (label expansions, lifecycle management, and manufacturing capacity upgrades)
Answer: Not determinable from the provided input.
Event-driven thesis checklist (PDUFA, exclusivity milestones, settlement outcomes, or regulatory approvals of generics)
Answer: Not determinable from the provided input.
Key Takeaways
Not determinable from the provided input.
FAQs
- What is the Orange Book patent expiration schedule for PROFERDEX? Not determinable from the provided input.
- Has any company filed a Paragraph IV challenge for PROFERDEX? Not determinable from the provided input.
- When could the first generic or follow-on product enter the U.S. for PROFERDEX? Not determinable from the provided input.
- Does PROFERDEX face biosimilar competition or only ANDA competition? Not determinable from the provided input.
- What patents protect PROFERDEX’s formulation and manufacturing process? Not determinable from the provided input.
References
Not determinable from the provided input.
